This is a study to assess safety and efficacy of ELAD in subjects with alcohol-induced liver decompensation (AILD)
This research is being done to determine the safety and the effectiveness of the ELAD system. ELAD is a machine that is designed to provide liver support continuously to a subject with liver failure, allowing time for the subject’s own liver to regenerate or to stabilize. This study specifically focuses on individuals with alcohol-induced liver decompensation (AILD). Overall, 200 patients will be recruited for this study. At Rush University Medical Center, we expect to enroll five patients. The treatment will be assigned randomly.
You may be eligible to participate in this study if you:
- Are 18 years of age or older
- Have signs and symptoms of alcohol-induced liver decompensation (AILD). AILD is a worsening of the chronic liver disease you already have
- Are not eligible for liver transplant
You will be excluded from this study if you:
- Have chronic, end-stage renal disease requiring chronic hemodialysis for more than eight weeks
- Have liver disease related to homozygous hemachromotosis, Wilson’s disease, non-alcoholic fatty liver disease or Budd-Chiari syndrome
- Have had a previous liver transplant
- Are unable to provide an address for follow-up home health visits
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.